Infinity Pharmaceuticals, Inc. (NASDAQ:INFI)

SideShowMel0329 (78.30) Submitted: 3/14/2013 12:32:20 PM : Start Price: $49.18 INFI Score: +55.63

What the hell is up with this stock? I don't understand why people throw their money at pharma's still in the early stages of the pipeline

marketarbitrage (77.87) Submitted: 7/6/2012 3:56:23 AM : Start Price: $15.02 INFI Score: -43.91

more jul12 long term plays

sell wholefoods & buy arden group (gelsons markets)
sell regeneron & infinity pharmaceuticals

IBDContrarian (20.82) Submitted: 6/27/2012 1:57:10 PM : Start Price: $13.60 INFI Score: -59.10

IBD EPS, RS, SPROE, Acc ratings plus P/E and div yield
MEDICAL 9 97 EB- NEG EARNINGS

phatchips767 (< 20) Submitted: 4/14/2012 3:56:15 PM : Start Price: $13.08 INFI Score: +70.85

80% increase since feb..

TMFUltraLong (99.97) Submitted: 3/27/2012 4:32:26 AM : Start Price: $12.18 INFI Score: -88.38

I feel like I've done this a few times before. I've lost count how many times I've bet against Infinity Pharmaceuticals, but here we go again. As usual we've got tons of hope built into the stock with multiple early and mid-clinical stage results due out this year... and right on cue the company has failed to live up to those expectations time and time again. When are traders going to just learn to stay away from Infinity?

TMFUltraLong

zzlangerhans (99.78) Submitted: 2/25/2012 12:18:37 AM : Start Price: $7.08 INFI Score: -233.03

Infinity, I'm not feeling a comeback here. You used to make a pretty good case as an Energizer Bunny, with more than 100M in cash reserves and two distinctive phase II oncology candidates. But that was before a string of failures for retaspimycin, and now saridegib is starting to take the same route. The cash position will be down to about 65M when the next quarterly numbers come out in a couple of weeks, and we know you like to raise money long before it's really necessary. And you want a 190M market cap for that? Call me back after the dilutive financing when the cap is closer to 150M and the share price back under 6, and we'll talk.

biotecher73 (< 20) Submitted: 5/20/2011 11:42:10 AM : Start Price: $6.79 INFI Score: +245.14

Stock is at a hard bottom with market cap less than or equal to cash on hand. Two clinical trials in play for its lead candidate and a backup portfolio behind that. Royalties are already coming in to make the company marginally profitable, and a single piece of good news is likely to send the company radically upward in valuation. Add to that a significant short ratio, and a short squeeze similar to ARIA in 2000 could easily occur.

EMG114 (< 20) Submitted: 4/23/2008 3:27:37 PM : Start Price: $7.04 INFI Score: +231.26

Good investment for the long-term...

tharlow (79.13) Submitted: 8/24/2007 3:42:26 AM : Start Price: $10.16 INFI Score: +127.21

This will be absolutely massive.

cardiacarrest (26.90) Submitted: 1/12/2007 10:32:50 AM : Start Price: $14.10 INFI Score: +53.36

Yes the madly ambitious Julian Adams at least has a track record to back up his new venture in Infinity. He and his sharp CEO have gone from basically nothing to on the market and in the clinic in 3 years. It should keep charging along....